Integrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways

Immunology and Microbiology

• Antigen Presentation 25%
• B Cell 75%
• Epstein Barr Virus 100%
• Gene Expression Assay 100%
• Genotype Phenotype Correlation 25%
• Human immunodeficiency virus 75%
• Interleukin 6 25%
• JAK-STAT Signaling 25%
• Major Histocompatibility Complex 25%
• mTOR Signaling 25%
• Multiple Myeloma 25%
• PDGFRB 25%
• RNA Sequence 50%
• RNA Sequencing 25%
• Somatic Mutation 25%
• STAT3 25%
• Tyrosine 25%
• Upregulation 25%
• Whole Exome Sequencing 50%

Biochemistry, Genetics and Molecular Biology

• Antigen Presentation 25%
• B Cell 75%
• Cell Cycle Regulation 25%
• ERBB3 25%
• Exome Sequencing 50%
• Gene Expression Profiling 100%
• Genotype Phenotype Correlation 25%
• Human immunodeficiency virus 75%
• Interleukin 6 25%
• JAK-STAT Signaling Pathway 25%
• Major Histocompatibility Complex 25%
• mTOR Signaling 25%
• Phosphoinositide 3-Kinase 25%
• Platelet Derived Growth Factor Receptor Beta 25%
• Receptor Tyrosine Kinase 25%
• RNA Sequence 50%
• RNA Sequencing 25%
• Somatic Mutation 25%
• STAT3 25%
• Transcription 25%
• Upregulation 25%

Medicine and Dentistry

• Aggressive Lymphoma 8%
• B Cell 16%
• Cell Cycle Regulation 8%
• Diffuse Large B-Cell Lymphoma 8%
• Exome Sequencing 16%
• Gene Expression Profiling 100%
• Human immunodeficiency virus 25%
• Interleukin 6 8%
• JAK-STAT Signaling 8%
• Multiple Myeloma 8%
• Neoplasm 8%
• Protein Tyrosine Kinase 8%
• RNA Sequence 16%
• RNA Sequencing 8%
• Upregulation 8%